Category: Uncategorized

The Goehring & Rozencwajg Resources Fund, launched last year, reaches milestone organically and without seeding

NEW YORK, May 16 (Bernama-BUSINESS WIRE) — Goehring & Rozencwajg, a natural resource investment firm, today announced that their UCITS fund, the Goehring & Rozencwajg Resources Fund (“the Fund”), has exceeded $100 million in assets under management in the year since its launch in May 2023.

The Fund has been available for qualified investors in the UK, Switzerland, Hong Kong, and Singapore. Application has been made to launch a UK feeder fund for the UK retail market and the Fund is undergoing registration for distribution in Germany. Utilizing the same investment philosophy as the U.S.-based Goehring & Rozencwajg Mutual Fund, the Fund invests predominantly in natural resource equities, including small- and mid-cap companies that they believe will be the biggest beneficiaries of any increase in the underlying commodity prices.

Notably, no seeding was used to reach this goal. The rapid organic growth of the fund may be attributed to the large global following that Goehring & Rozencwajg has accumulated over the years in the commodities markets due to their research and thought leadership.

“We are proud to achieve the $100 million milestone with the UCITS fund in such a short time,” said Adam Rozencwajg, Managing Partner of Goehring & Rozencwajg. “The Fund is seeing outstanding growth on the backs of our large international audience, who finally had the opportunity to invest with us last year. We are excited to continue to drive returns for our investors at home and abroad.”

Rozencwajg continued, “Following years of underinvestment, the extractive industries have been starved of capital and new sources of supply to fuel global development have not come online. We believe we are at the beginning of the bull market across the spectrum but choosing the right sectors to commit capital in the short to medium term is critical for investors who wish to capture the attractive returns available.”

About Goehring & Rozencwajg:

Goehring & Rozencwajg is a natural resource investment firm that utilizes proprietary research to uncover value in commodities with a contrarian investment philosophy. With over 45 years of combined experience in natural resource investment, Goehring & Rozencwajg strives to deliver top-quartile performance in their peer group over a 3-5 year time horizon. They currently manage $650 million on behalf of their clients. Their research can be viewed at www.gorozen.com/blog.

View source version on businesswire.com: 
https://www.businesswire.com/news/home/20240515709212/en/

Contact

Media:
Rich Myers
Profile Advisors
GoehringRozencwajg@profileadvisors.com

Source : Goehring & Rozencwajg

KUALA LUMPUR, May 15 (Bernama) — Cvent, an industry-leading meetings, events, and hospitality technology provider, released its lists of the Top Meeting Destinations and Top Meeting Hotels for Asia Pacific (APAC), with Kuala Lumpur and Hilton Kuala Lumpur ranked seventh and eighth, respectively.

The top 10 cities remained mostly consistent year-over-year with Singapore retaining its first position from 2023, while the sole newcomer to the list is Shanghai, China at 10th place.

According to Cvent in a statement, Bangkok, Thailand (No. 2), Tokyo, Japan (No. 4), Kuala Lumpur, Malaysia (No. 7) and Phuket, Thailand (No. 9) each improved their top 10 rankings from 2023.

Meanwhile, JW Marriott Hotel Singapore South Beach rose in the Top 10 Meeting Hotels ranking to secure this year’s top spot, as the hotel’s proximity to the Central Business District, cutting-edge audio-visual offerings and flexible meeting space make it an ideal host venue for event planners.

Newcomers to the top 10 include Hilton Tokyo (No. 4), Bangkok Marriott Marquis Queen’s Park (No. 5), voco Orchard Singapore (No. 7), Hilton Kuala Lumpur (No. 8), and Sheraton Grand Sydney Hyde Park (No. 9).

These lists, which also include regional rankings for North America, Europe, and the Middle East & Africa, were compiled based on sourcing activity through the Cvent Supplier Network, one of the world’s largest venue-sourcing platforms.

The annual Cvent Top Lists have become go-to resources for event organisers worldwide looking for incredible hotels and destinations to host their events.

Cvent has evaluated more than 12,500 cities worldwide listed on the Cvent Supplier Network (CSN) for Cvent Top Meeting Destinations, in which activity was tracked between January 2023 and December 2023.

For Cvent Top Meeting Hotels, Cvent evaluated hotel properties that generated business through the CSN in the same period with properties ranked according to various criteria, including total requests for proposals (RFPs), awarded RFPs, and total room nights.

— BERNAMA

KUALA LUMPUR, May 14 (Bernama) — King Faisal Specialist Hospital and Research Centre (KFSH&RC) Chief Executive Officer (CEO), Dr Majid Al Fayyadh recently showcased the hospital’s journey since its inception in Riyadh almost five decades ago, highlighting how it has significantly reduced the need for patients to travel abroad for medical care.

During the Gulf Creatives Conference (GCC) at Harvard 2024, organised by The Diwan, an organisation run by Harvard University’s graduate students, Dr Al Fayyadh also discussed KFSH&RC’s transformation into an independent, non-profit foundation.

He indicated that this move aligns with the organisation’s strategic vision to become a global healthcare innovation leader, emphasising excellence, innovation, as well as investment in cutting-edge technology to tackle global health challenges.

“The Saudi Leadership has outlined a clear vision for KFSH&RC, mandated by a royal decree transitioning the hospital into an independent Sui Generis, non-profit foundation,” said Dr Al Fayyadh in a statement.

He further highlighted that this transformation seeks to elevate global healthcare standards through increased independence and flexibility.

This shift will allow the hospital to optimise existing services, pursue new opportunities, and direct resources toward initiatives that promote human health and well-being both within the Kingdom and internationally, in addition to reinforcing KFSH&RC’s dedication to patient-centered excellence.

Dr Al Fayyadh pointed out that KFSH&RC envisions itself as a leader in maximising the value of healthcare spending, adhering to evidence-based practices to ensure optimal patient outcomes as it seeks to remain at the forefront of global healthcare innovation, with initiatives designed to increase health equity and access worldwide.

He also joined a panel discussion focusing on the evolving landscape of the healthcare sector and the positive outcomes of KFSH&RC’s ongoing transformation in patient care, while also highlighting the effective role of the hospital’s transformative initiatives in aligning with the objectives of the Health Sector Transformation Program and Saudi Vision 2030.

KFSH&RC is dedicated to developing medical technologies and elevating healthcare standards worldwide, forging partnerships with leading local, regional, and international institutions to deliver world-class services in clinical, research and educational domains.

— BERNAMA

KUALA LUMPUR, May 14 (Bernama) — King Faisal Specialist Hospital and Research Centre (KFSH&RC) has appointed Dr Björn Zoéga as its Deputy Chief Executive Officer (CEO), underscoring its commitment to promote and foster healthcare excellence.

Renowned for his extensive experience in healthcare management and policy, Dr Zoéga joins a dedicated team as the hospital continues to drive key strategic initiatives, according to a statement.

As a leader in medical research and clinical services, KFSH&RC continues to attract global expertise to bolster its vision of healthcare excellence, and with Dr Zoéga’s involvement, the hospital is advancing a digital transformation strategy designed to improve operational efficiency and enhance patient care.

His expertise in fostering international collaborations, evidenced by his former role as president of the European University Hospital Alliance (EUHA) and through initiatives like JOIN4ATMP aimed at advancing access to innovative therapies, further aligns KFSH&RC’s services with global healthcare trends.

Dr Zoéga’s previous contributions at Karolinska University Hospital, which is ranked the second best in Europe and seventh globally by Newsweek’s 2024 World’s Best Hospitals, where he nurtured a culture of continuous learning and collaboration among healthcare professionals, align well with KFSH&RC’s objectives.

His role in fostering programmes like EUCARE and facilitating the Europe-wide exchange of intensive care nurses during crises has significantly enhanced staff development and supported his previous hospital’s goal of attracting top talent, a principle mirrored in KFSH&RC’s transformation journey.

With Dr Zoéga contributing to leadership, KFSH&RC is poised to further its role as a pivotal player in shaping the future of healthcare in Saudi Arabia.

Key projects at KFSH&RC include the deployment of advanced digital technologies to streamline the patient care process, the adoption of innovative care models, and the upgrading of facility amenities, aiming to improve access to medical services and facilitate better communication, reflecting KFSH&RC’s dedication to setting new standards in healthcare.

— BERNAMA

RIYADH, Saudi Arabia, May 13 (Bernama-GLOBE NEWSWIRE) — King Faisal Specialist Hospital & Research Centre (KFSH&RC) has experienced a year of achievements across its three Centres of Excellence—Oncology, Genomics, and Transplantation.

KFSH&RC’s Oncology Centre of Excellence continues to lead the fight against the disease in the Kingdom. This year alone, the centre has treated 25% of all cancer cases in Saudi Arabia, achieving a 50% overall recovery rate and up to 90% recovery in leukemia cases. With almost five decades of service, the centre’s commitment to providing advanced cancer treatments is evident in its adoption of technologies such as CAR T-cell therapy and liquid biopsy, which provide less invasive alternatives to traditional methods, along with extensive bone marrow transplants, and revolutionary techniques like Hyperthermic Intraperitoneal Chemotherapy (HIPEC).

Notably, KFSH&RC has achieved a milestone by completing over 100 CAR T-cell therapy procedures, a novel treatment that genetically modifies a patient’s immune cells to fight cancer. This achievement puts it on par with renowned institutions that are also advancing CAR-T cell therapy for various blood cancers and exploring expanded applications through clinical trials and new treatment protocols. Furthermore, the centre’s focus on pediatric oncology boasts a 97% five-year survival rate for renal tumors and a 92% survival rate for acute lymphoblastic leukemia in children.

With rapid advancements in genomic medicine, KFSH&RC is adopting next-generation sequencing technologies into patient care in its Genomic Centre, revolutionizing local and regional approaches to disease management. KFSH&RC’s discovery of the bacterial strain Stenotrophomonas Riyadhensis, facilitated by whole-genome sequencing (WGS) technology, has contributed to our understanding of bacterial antibiotic resistance mechanisms. With 15,698 patient visits and over 5,658 whole genomes completed in 2023, the centre ensures that prevention, diagnosis, and treatment are precise and personalized.

KFSH&RC’s Organ Transplant Centre of Excellence (OTCoE) continues to be the primary contributor to organ transplantation activities in the Kingdom, accounting for 65% of all transplants performed nationally. In 2023, OTCoE performed 1,092 solid organ transplants, including the world’s first fully robotic liver transplant— where doctors employed robotic technology to conduct surgery on both patient and donor — an achievement that places the centre at the forefront of global transplantation practices.

As KFSH&RC continues to push the boundaries of what is possible in medical science, its efforts not only inspire but also significantly impact the global healthcare community, reaffirming its role as a leader in medical innovation and specialized healthcare.

About King Faisal Specialist Hospital & Research Centre (KFSH&RC):

King Faisal Specialist Hospital & Research Centre (KFSH&RC) stands as a leading healthcare institution in the Middle East, envisioned to be the optimal choice for every patient seeking specialized healthcare. The hospital boasts a rich history in the treatment of cancers, cardiovascular diseases, organ transplantation, neurosciences, and genetics.

In 2024, “Brand Finance” ranked King Faisal Specialist Hospital & Research Centre as the top academic medical centre in the Middle East and Africa, and among the top 20 globally for the second consecutive year. Additionally, in 2024, it was recognized as one of the leading global healthcare providers by Newsweek magazine.

As part of Saudi Vision 2030, a royal decree was issued on December 21, 2021, to transform the hospital into an independent, non-profit, government-owned entity, paving the way for a comprehensive transformation program aimed at achieving global leadership in healthcare through excellence and innovation.

CONTACT INFORMATION

For more information, please contact:

Mr. Essam Al-Zahrani, Acting Media Affairs Head, 0555254429

Mr. Abdullah Al-Aown, Media Coordination Officer, 0556294232

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e99afd2f-d5c6-400e-9290-26b36a580bee

SOURCE: King Faisal Specialist Hospital & Research Centre

–BERNAMA